XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration and License Agreement - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Nov. 06, 2020
Mar. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Collaboration and license agreement date   Nov. 06, 2020  
Collaborative arrangement, rights and obligations The Company will also be entitled to receive tiered royalties ranging from low double digits to mid-teens on sales in the Territory, if any, of products containing AVB-500. Royalties are payable with respect to each jurisdiction in the Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Territory; or (iii) ten (10) years after the first commercial sale of a product in such jurisdiction in the Territory. In addition, royalties payable under the Agreement will be subject to reduction on account of generic competition under certain specified conditions, with any such reductions capped at certain percentages of the amounts otherwise payable during the applicable royalty payment period.    
Transaction Price $ 12,000    
Research and development services performance obligation 6,400    
Intellectual property obligation 5,600    
Assessed clinical or regulatory milestones   $ 0  
3D Medicines [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Revenue from research and development services   300  
Contract Liability   6,000  
Contract Liability, current   2,400  
Contract Liability, long-term   $ 3,600  
Service period for future research and development services expected to occur   2 years 2 months 12 days  
3D Medicines [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Collaborative agreement milestone cash payment 12,000    
Proceeds from Collaborators     $ 12,000
3D Medicines [Member] | Maximum [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Clinical development, regulatory and commercial milestone payments $ 207,000    
Stanford University [Member]      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Collaborative agreement milestone cash payment due   $ 132